Lead author, Dr. Philip Mease, MD, Director of Rheumatology Research at the Swedish Medical Center/Providence St. Joseph Health and Clinical Professor at the University of Washington School of Medicine, discusses new data from the Phase 3 DISCOVER-1 and DISCOVER-2 studies published in “The Lancet Rheumatology” (July 2021) on the efficacy of guselkumab on axial symptoms in patients with active psoriatic arthritis. Up to 70% of PsA patients experience axial symptoms.
Philip J Mease, MD, is a Clinical Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Center in Seattle, WA. Dr Mease’s clinical practice is based at Seattle Rheumatology Associates. He received his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as chief resident and fellow in rheumatology. Dr Mease conducts clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus. He also conducts research in disease state metrics and is the co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment, as well as a member of the Soluble Biomarker working group. Dr Mease is a founding organizer and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles.
Listen on Soundcloud.